Panacea Bio gets DCGI nod to make Sputnik V
Panacea Biotec is one of six companies to have entered into partnerships with the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund that is marketing the vaccine globally.
The Drugs Controller General of India has granted Panacea Biotec the licence to manufacture the Russian-made Covid vaccine Sputnik V in India, the company announced on Sunday, making it the first firm that will manufacturing the vaccine locally.
Panacea Biotec is one of six companies to have entered into partnerships with the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund that is marketing the vaccine globally.
“Panacea Biotec… (is in) receipt of manufacturing licence from Drugs Controller General (India) for Sputnik V vaccine against Covid-19 pursuant to its collaboration with Russian Direct Investment Fund. The licence is a necessary condition for using Sputnik V produced by Panacea Biotec in India,” the pharma company said in a statement.
Click here for full Covid-19 coverage
The two-dose vaccine has 91.6% efficacy in preventing serious illness.
The initial test batches produced at Panacea Biotec’s facilities at Baddi in Himachal Pradesh were earlier shipped to the Gamaleya Center in Russia for quality control.
“The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli, Himachal Pradesh in India,” the company statement read.
Even though the company did not respond to further queries on when the vaccine will be available, people familiar with the matter, on condition of anonymity, said that under its terms with RDIF, Panacea is likely to produce 100 million doses per year. Dr Reddy’s Laboratories that has tied up with RDIF to market the first 250 million doses of the Russian vaccine, is also likely to market the doses produced by Panacea. Sputnik V was registered in India under the emergency use authorisation procedure on April 12 and vaccination against Covid-19 with the Russian vaccine started on May 14.
As part of the soft launch, the vaccine has been administered in several Indian cities so far, including Visakhapatnam, Bengaluru, Mumbai, Kolkata, Delhi, Baddi, Chennai, Miryalaguda, and Kolhapur. Sputnik V has been registered in 67 countries globally with total population of over 3.5 billion people.
ABOUT THE AUTHORRhythma KaulRhythma Kaul is the national health editor of the Hindustan Times. She has been reporting on public health, medicine, and medical research, with a particular focus on how government decisions and health system reforms shape people’s lives. Rhythma has over 25 years of journalistic experience. She joined Hindustan Times in 2008, and has since covered everything from pandemics and infectious diseases to cutting‑edge medical research and climate‑related health challenges. Her stories routinely track the work of the Ministry of Health and Family Welfare, department of pharmaceuticals, and key national health programmes, making complex medical science and policy accessible to a wide audience. One of her prominent news breaks has been the 2012 Baby Falak case: A two-year-old brutally battered baby girl was admitted to AIIMS-Delhi with severe head injuries, multiple fractures, human bite marks, and burns. The police investigation revealed this to be a case of multi-state human-trafficking racket. She was profiled by The Wall Street Journal for breaking this story. Rhythma holds a Master’s degree from Jawaharlal Nehru University, Delhi. Prior to Hindustan Times, she worked with the India Today Group. Rhythma can be contacted at rhythma.kaul@hindustantimes.com. Her X handle is @RamblingBrook.Read More

E-Paper


